SCYX Dana dhuwit perusahaan SCYNEXIS, Inc.

Logo grafis scynexis.com (SCYX)

SCYNEXIS, Inc. (SCYX) revenues are based on Brexafemme sales and payments from GSK. The cash balance illustrates the resource dynamics for operating activities, where 0.05 is the current level of this metric. Stability is ensured by exclusive patents for next-generation antimycotics. Minimal geopolitical risks and operations within the US legal framework guarantee the protection of intellectual property.

SCYX - Dhuwit awis perusahaan SCYNEXIS ing rentang 04.07.2022 - 21.11.2026

SCYNEXIS, Inc. (SCYX) - rincian metrik lan laporan keuangan

- nilai saham lan prakiraan konsensus rega:
Analisis kabeh metrik perusahaan:scynexis.com SCYX
Produk mawa merek Scynexis

Fundamental asset selection requires precise liquidity monitoring to assess a business's ability to service its obligations without external financing. This indicator measures actual cash volume, determining the capital burn rate of SCYNEXIS, Inc. (SCYX) given its narrow specialization in a single platform, which allows for an assessment of the licensing model's sustainability via current cash reserves in the absence of operational growth.